TUESDAY, July 6, 2023 (HealthDay News) — The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, new clinical trial results show.
Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% at one year compared to 86%, said lead researcher Dr. Alex Herrera, a hematologist-oncologist at City of Hope in Duarte, Calif.
Nivolumab also produced significantly fewer side effects than brentuximab vedotin, which was the first novel therapy developed for Hodgkin lymphoma, Herrera said in a presentation Sunday at the American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
Leave a reply